Expertise in
13
conditions

Dr. Stephen L. Richey

Oncology | Hematology | Internal Medicine
Fort Worth, TX 
Offers Telehealth
Expertise in
13
conditions
Fort Worth, TX 

Overview

Stephen Richey is a Hematologist and an Oncologist in Fort Worth, Texas. Dr. Richey is highly rated in 13 conditions, according to our data. His top areas of expertise are Myelodysplastic Syndrome (MDS), Colorectal Cancer, Hemangioma Thrombocytopenia Syndrome, Adult Immune Thrombocytopenia, and Nephrectomy.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 24 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

LSU School Of Medicine - 2004

Residency

Internal Medicine, University of Texas Medical School Houston - 2008

Specialties

Oncology
Hematology
Internal Medicine

Licenses

Internal Medicine in TX

Board Certifications

Medical Oncology- American Board Of Internal Med/Medical Oncology
Hematology- American Board Of Internal Med/Hematology

Fellowships

Hematology/Oncology, University of Texas MD Anderson Cancer Center - 2011

Hospital Affiliations

Baylor Scott & White All Saints Medical Center - Fort Worth

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Moda Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Scott and White Health
  • HMO
  • POS
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Texas Oncology, P.A.
Fort Worth, TX 76104
Other Locations
Texas Oncology, P.A.
191 Walls Dr, Cleburne, TX 76033

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

23 Clinical Trials

A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Completed
Publish Date: February 03, 2026
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Drug
Study Drugs: TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel
Study Phase: Phase 1
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Study Phase: Phase 2/Phase 3
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 1
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
Enrollment Status: Completed
Publish Date: November 19, 2024
Intervention Type: Biological, Other
Study Drugs: Galinpepimut-S, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drugs: SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab
Study Phase: Phase 1
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drug: STRO-001
Study Phase: Phase 1
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, IPI-549, Pegylated liposomal doxorubicin, Nab-paclitaxel
Study Phase: Phase 1
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1a / 1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients With Advanced Solid Tumors
A Phase 1a / 1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: TP-0903
Study Phase: Phase 1
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Combination product
Study Drugs: Alvocidib, Decitabine, Azacitidine
Study Phase: Phase 1/Phase 2
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Unknown
Publish Date: September 13, 2023
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
Enrollment Status: Terminated
Publish Date: July 06, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: November 04, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
Enrollment Status: Completed
Publish Date: August 05, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors
A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: March 09, 2021
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: March 12, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 22 Less Clinical Trials

9 Total Publications

A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
Journal: Breast cancer research and treatment
Published: July 09, 2019
Similar Doctors
Expertise in
39
conditions
Dr. Farrukh Awan
Hematology | Oncology
Expertise in
39
conditions
Dr. Farrukh Awan
Hematology | Oncology

UT Southwestern-Bill And Rita Clements Advanced Medical Imaging Center

2201 Inwood Rd, 
Dallas, TX 
 (29.3 miles away)
214-645-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Farrukh Awan is a Hematologist and an Oncologist in Dallas, Texas. Dr. Awan is highly rated in 39 conditions, according to our data. His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
9
conditions
Dr. Naomi Winick
Hematology | Oncology
Expertise in
9
conditions
Dr. Naomi Winick
Hematology | Oncology

Children's Medical Center/Children's Health

1935 Medical District Dr, 
Dallas, TX 
 (29.5 miles away)
214-648-3896
Languages Spoken:
English
See accepted insurances

Naomi Winick is a Hematologist and an Oncologist in Dallas, Texas. Dr. Winick is highly rated in 9 conditions, according to our data. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Infantile Neutropenia, Febrile Neutropenia, and Bone Marrow Transplant.

Expertise in
11
conditions
Dr. Alecia Nero
Hematology | Oncology
Expertise in
11
conditions
Dr. Alecia Nero
Hematology | Oncology

University Of Texas Southwestern Medical Center

5323 Harry Hines Blvd, 
Dallas, TX 
 (29.4 miles away)
214-648-4180
Languages Spoken:
English
See accepted insurances

Alecia Nero is a Hematologist and an Oncologist in Dallas, Texas. Dr. Nero is highly rated in 11 conditions, according to our data. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Stephen L. Richey

How do I make an appointment with Dr. Stephen L. Richey?

You can book an appointment with Dr. Stephen L. Richey by calling their office at 817-413-1500. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Stephen L. Richey a top-rated expert for Myelodysplastic Syndrome (MDS)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Stephen L. Richey is classified as an Advanced expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Stephen L. Richey specialize in?

While Dr. Stephen L. Richey is a Oncology, they have specific expertise in Myelodysplastic Syndrome (MDS), Colorectal Cancer, and Hemangioma Thrombocytopenia Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Stephen L. Richey participate in research or clinical trials?

Yes. Dr. Stephen L. Richey has published 9 articles and abstracts on conditions like Myelodysplastic Syndrome (MDS). You can view a list of Dr. Stephen L. Richey's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Stephen L. Richey accept my insurance?

Dr. Stephen L. Richey accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 817-413-1500 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Richey's expertise for a condition
ConditionClose
      View All 13 Advanced Conditions
      View All 70 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile